Consistent with the decrease in NT-proBNP, LVEF increased in our study after medication with ARNI regardless of HF etiology at one-year follow-up (in the ICMP group, from 24.13% ± 8.39 to 32.13% ± 7.53, and in the NICMP group, from 25.31% ± 7.68 to 29.63% ± 10.01). This evidence concerns the gene NPPB and hydrops fetalis.